Today, Folia Health and Novartis Pharmaceuticals, Inc. proudly announce their collaboration on an innovative, at-home ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic ...

Haseeb Ahmad brings over 25 years of leadership experience in life sciences, most recently serving as President of Novartis ...

Travere Therapeutics' Filspari boosts revenue with FDA approval, but heavy losses and competitive threats raise concerns for ...

World Kidney Day was observed at GMCH highlighting the escalating prevalence of Chronic Kidney Disease (CKD) in Assam. Physicians emphasize the need for further investigation into CKD's unknown ...

Novartis spokesperson told News18 that the company is in the process of reviewing the minutes of the meeting and post ...

Guwahati: Physicians at Gauhati Medical College and Hospital (GMCH) have flagged elevated instances of Chronic Kidney Disease ...

Gauhati Medical College and Hospital observed World Kidney Day, addressing the rising cases of Chronic Kidney Disease (CKD) ...

Beyond AMR, Biogen is planning to initiate phase 3 trials of felzartamab in two kidney diseases, IgA nephropathy and primary ...

The success of a kidney transplant largely depends on patient awareness, consistent care, and adherence to medical advice ...

CAMBRIDGE, MA, USA I March 11, 2025 I Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase ...

Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigational RNA interference (RNAi) candidate was ...